Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial ; volume:22 ; number:1 ; day:11 ; month:11 ; year:2020 ; pages:1-14 ; date:12.2020
Breast cancer research ; 22, Heft 1 (11.11.2020), 1-14, 12.2020
- Creator
-
Quintela-Fandino, Miguel
Holgado, Esther
Manso, Luis
Morales, Serafin
Bermejo, Begoña
Colomer, Ramon
Apala, Juan V.
Blanco, Raquel
Muñoz, Manuel
Caleiras, Eduardo
Iranzo, Vega
Martinez, Mario
Dominguez, Orlando
Hornedo, Javier
Gonzalez-Cortijo, Lucia
Cortes, Javier
Gasol Cudos, Ariadna
Malon, Diego
Lopez-Alonso, Antonio
Moreno-Ortíz, María C.
Mouron, Silvana
Mañes, Santos
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-020-01362-y
- URN
-
urn:nbn:de:101:1-2020122219294576776526
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Quintela-Fandino, Miguel
- Holgado, Esther
- Manso, Luis
- Morales, Serafin
- Bermejo, Begoña
- Colomer, Ramon
- Apala, Juan V.
- Blanco, Raquel
- Muñoz, Manuel
- Caleiras, Eduardo
- Iranzo, Vega
- Martinez, Mario
- Dominguez, Orlando
- Hornedo, Javier
- Gonzalez-Cortijo, Lucia
- Cortes, Javier
- Gasol Cudos, Ariadna
- Malon, Diego
- Lopez-Alonso, Antonio
- Moreno-Ortíz, María C.
- Mouron, Silvana
- Mañes, Santos
- SpringerLink (Online service)
Other Objects (12)
Arzneimittel Profil Durvalumab
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Retinal Vasculitis Secondary to Durvalumab
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Priming
Arzneimittel Profil Durvalumab
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Retinal Vasculitis Secondary to Durvalumab
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Priming
Arzneimittel Profil Durvalumab
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Retinal Vasculitis Secondary to Durvalumab
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine